The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by motoneuron degeneration, resulting in muscle paralysis and death, typically within 1–5 years of diagnosis. Although the pathogenesis of ALS remains unclear, there is evidence for the involvement of proteasome dysfunction and heat shock proteins in the disease. We have previously shown that treatment with a co‐inducer of the heat shock response called arimoclomol is effective in the SOD G93A mouse model of ALS, delaying disease progression and extending the lifespan of SOD G93A mice (Kieran et al. 2004). However, this previous study only examined the effects arimoclomol when treatment was initiated in pre‐ or early symptomatic stages of the disease. Clearly, to be of benefit to the majority of ALS patients, any therapy must be effective after symptom onset. In order to establish whether post‐symptomatic treatment with arimoclomol is effective, in this study we carried out a systematic assessment of different treatment regimes in SOD G93A mice. Treatment with arimoclomol from early (75 days) or late (90 days) symptomatic stages significantly improved muscle function. Treatment from 75 days also significantly increased the lifespan of SOD G93A mice, although treatment from 90 days has no significant effect on lifespan. The mechanism of action of arimoclomol involves potentiation of the heat shock response, and treatment with arimoclomol increased Hsp70 expression. Interestingly, this up‐regulation in Hsp70 was accompanied by a decrease in the number of ubiquitin‐positive aggregates in the spinal cord of treated SOD G93A mice, suggesting that arimoclomol directly effects protein aggregation and degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Cited by
Regulation of superoxide dismutase genes: Implications in disease
Miao, L., & St. Clair, D. K. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.018 · Cited by 912
Heat shock transcription factor 1 as a therapeutic target in neurodegenerative diseases
Neef, D. W., Jaeger, A. M., & Thiele, D. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3453 · Cited by 307
Mitchell, J. C., McGoldrick, P., Vance, C., Hortobagyi, T., Sreedharan, J., Rogelj, B., Tudor, E. L., Smith, B. N., Klasen, C., Miller, C. C. J., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-012-1043-z · Cited by 289
Self-citationRiluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Heat shock protein–based therapy as a potential candidate for treating the sphingolipidoses
Kirkegaard, T., Gray, J., Priestman, D. A., Wallom, K.-L., Atkins, J., Olsen, O. D., Klein, A., Drndarski, S., Petersen, N. H. T., Ingemann, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9823 · Cited by 173
Metadata
- Authors
- Kalmar, B., Novoselov, S., Gray, A., Cheetham, M. E., Margulis, B., & Greensmith, L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 107
- Issue
- 2
- Pages
- 339-350
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1511318907
- Cited by
- 166
- References
- 1
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS. https://app.cochat.ai/papers/10.1111/j.1471-4159.2008.05595.x
- The paper
- Kalmar, B., Novoselov, S., Gray, A., Cheetham, M. E., Margulis, B., & Greensmith, L. (2008). Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1G93A mouse model of ALS. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2008.05595.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.